和誉医药：完成依帕戈替尼治疗 HCC 的注册性临床试验首例患者给药
和誉在港交所公告，附属公司上海和誉生物医药科技有限公司宣布已完成其自主研发的高选择性小分子 FGFR4 抑制剂依帕戈替尼治疗肝细胞癌（HCC）的注册性临床试验的首例患者给药。依帕戈替尼于 2025 年 5 月获中国国家药品监督管理局药品审评中心突破性疗法认定。依帕戈替尼也是首个采用靶向分子生物标志物精准治疗 HCC 的药物。
BY 财经慢报
In many cases, the content resembled that of the marketplaces found on the dark web, a group of hidden websites that are popular among hackers and accessed using specific anonymising software.“We have recently been witnessing a 100 per cent-plus rise in Telegram usage by cybercriminals,” said Tal Samra, cyber threat analyst at Cyberint.The rise in nefarious activity comes as users flocked to the encrypted chat app earlier this year after changes to the privacy policy of Facebook-owned rival WhatsApp prompted many to seek out alternatives.
Secret Chats are one of the service’s additional security features; it allows messages to be sent with client-to-client encryption. This setup means that, unlike regular messages, these secret messages can only be accessed from the device’s that initiated and accepted the chat. Additionally, Telegram notes that secret chats leave no trace on the company’s services and offer a self-destruct timer.
财经慢报 from us